NasdaqGS:NBIXBiotechs
A Look At Neurocrine Biosciences (NBIX) Valuation After Positive Analyst Views And 2026 Guidance
Neurocrine Biosciences (NBIX) is back in focus after reporting fourth quarter and full year 2025 earnings, alongside fresh 2026 sales guidance for INGREZZA and optimistic commentary around its late stage pipeline.
See our latest analysis for Neurocrine Biosciences.
At a latest share price of US$128.38, Neurocrine Biosciences has seen short term share price pressure, with a 30 day share price return of a 5.73% decline and a 90 day share price return of a 10.56% decline. However, a 1 year total...